Literature DB >> 28518220

Postdonation iron replacement for maintaining iron stores in female whole blood donors in routine donor practice: results of two feasibility studies in Australia.

Sant-Rayn Pasricha1,2, Denese C Marks3, Hannah Salvin2, Tania Brama2, Anthony J Keller2, Joanne Pink2, Joanna Speedy2.   

Abstract

BACKGROUND: Iron deficiency represents a risk to donor health and the blood supply. Efficacy trials indicate that postdonation iron replacement improves iron stores but they do not account for complexities of implementation in the routine collection context. We therefore conducted two prospective feasibility studies in Australian donor centers. STUDY DESIGN AND METHODS: In both studies we recruited female donors between 18 and 45 years who had made at least one donation in the previous 12 months. In READ (replacement advice), female donors were given a recommendation to self-procure postdonation iron. In DIRECT (donor iron replacement), donors were provided with a course of iron supplements. Donors could return to donate at their discretion and were surveyed after the recruitment visit and again toward the end of the 13-month follow-up. Donor uptake, adverse effects, effectiveness in maintaining iron stores, and workflow impact were assessed.
RESULTS: We recruited 1404 (70.9% of invited) donors to READ and 768 (53.2% of invited) to DIRECT. READ and DIRECT extended predonation interviews by 1 and 5 minutes, respectively. Among participants, 44 and 88% took iron in READ and DIRECT, respectively. Adverse effects were common but usually mild. READ failed to maintain iron stores in the population, but was effective in donors who consumed more than 75% of the recommended dose. DIRECT was effective in preventing declines in ferritin concentration.
CONCLUSION: Trade-offs between cost, complexity, uptake, and effectiveness must be considered in the implementation of postdonation iron supplementation.
© 2017 AABB.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28518220     DOI: 10.1111/trf.14173

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  6 in total

1.  ABO system combination with Rh, Kell and MN group in Georgian blood donors.

Authors:  Marina Nagervadze; Irine Tsintsadze; Leila Akhvlediani; Tea Koiava; Sophiko Tskvitinidze; Rusudan Khukhunaishvili; Marina Koridze
Journal:  Am J Blood Res       Date:  2021-04-15

2.  Association of blood donation with iron deficiency among adolescent and adult females in the United States: a nationally representative study.

Authors:  Eshan U Patel; Jodie L White; Evan M Bloch; Mary K Grabowski; Eric A Gehrie; Parvez M Lokhandwala; Patricia A R Brunker; Ruchika Goel; Beth H Shaz; Paul M Ness; Aaron A R Tobian
Journal:  Transfusion       Date:  2019-02-18       Impact factor: 3.157

3.  Iron supplementation limits the deleterious effects of repeated blood donation on endurance sport performance but not on iron status.

Authors:  Barbara Pachikian; Damien Naslain; Nicolas Benoit; Romain Brebels; Kristin Van Asch; Veerle Compernolle; Philippe Vandekerckhove; Louise Deldicque
Journal:  Blood Transfus       Date:  2020-07-22       Impact factor: 3.443

4.  The effect of donation activity dwarfs the effect of lifestyle, diet and targeted iron supplementation on blood donor iron stores.

Authors:  Muriel Lobier; Johanna Castrén; Pia Niittymäki; Elina Palokangas; Jukka Partanen; Mikko Arvas
Journal:  PLoS One       Date:  2019-08-13       Impact factor: 3.240

5.  Ferritin-guided iron supplementation in whole blood donors: optimal dosage, donor response, return and efficacy (FORTE)-a randomised controlled trial protocol.

Authors:  Jan Karregat; Maike G Sweegers; Franke A Quee; Henriëtte H Weekamp; Dorine W Swinkels; Vĕra M J Novotny; Hans L Zaaijer; Katja van den Hurk
Journal:  BMJ Open       Date:  2022-03-09       Impact factor: 2.692

6.  The effects of intravenous iron supplementation on fatigue and general health in non-anemic blood donors with iron deficiency: a randomized placebo-controlled superiority trial.

Authors:  Peter Keller; Roland von Känel; Cesar A Hincapié; Bruno R da Costa; Peter Jüni; Tobias E Erlanger; Nicola Andina; Christoph Niederhauser; Bernhard Lämmle; Stefano Fontana
Journal:  Sci Rep       Date:  2020-08-26       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.